Q-linea develops and delivers innovative solutions for the diagnosis of infectious diseases, with a keen focus on improving sepsis treatment while reducing antibiotic resistance
Q-linea is a company that develops innovative solutions for improved infectious disease diagnostics. The company focuses on developing instruments and consumables that benefit patients, healthcare providers and society. Q-linea develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company’s leading product, ASTar®, is a fully automated instrument for antimicrobial susceptibility testing, which produces a sensitivity profile from a positive blood culture within ~six hours. This is 24 to 40 hours faster than current diagnostics.
2007
Served areaWorldwide
29,537,947
IPODec. 7, 2018
Stock exchange(s)Nasdaq Stockholm